outcome) compared with another phenotype (unfavorable outcome) constitutes a strong evidence of genetic association. However, genetic association does not necessarily mean gene identification. It may, for example, be the result of stratification bias, linkage disequilibrium with the causative variant, or other inherent limitations of association studies.
14 A genetic association study requires biological evidence and functional significance that the risk variant is implicated in the pathogenesis of the disease. Susceptibility genes are expected to have weak effects and account for only a small or modest increase in risk (OR 1.2-1.4). Moreover, gene functions can be modified by other genes (gene-gene interactions), proteins (protein-protein interactions), or environmental factors (gene-environment interactions), and these modifications render the detection of their effects more difficult.
In general, there are 2 approaches to perform genetic association studies: the candidate-gene approach (also known as the hypothesis-driven approach) and the genome-wide approach (also known as the agnostic approach). In the candidate-gene approach, a few SNPs are genotyped on a gene of interest, which is chosen based on a biological hypothesis for the disease. On the other hand, genome-wide association studies attempt to survey the entire genome at the same time, in a hypothesisfree manner, using hundreds of thousands of SNPs. 94 Candidate-gene association studies are generally small in sample size and presumably have the tendency to lack the statistical power to detect a significant association. For example, to achieve a greater than 80% statistical power to identify a modest genetic effect (OR 1.2) of a polymorphism present in 10% of individuals, a sample size of 10,000 patients or more is necessary. 140 Therefore, the sample sizes required to predict associations have to be far beyond what is currently available, and no single institution is able to provide a statistically powerful association study. Strategies to overcome this problem and to increase the large sample size limitation include metaanalyses of multiple studies, 140 or collaborative, multiinstitutional, larger-scale studies and consortia, which allow pooling of data. 31, 77 Another approach to increase the power of genetic association studies is by implementing haplotype analysis, which subdivides the studied group into more genetically distinct subcategories. In addition, the statistical power of a study can be increased using well-defined intermediate phenotypes, which may be closer to the TBI pathophysiology and the pathogenic genotype, instead of the clinical phenotype, which is complex and multifactorial. Intermediate phenotypes used in TBI association studies include, for example, the Aβ-peptide deposits, 100 the hematoma volume, 69 or the presence of brain hemorrhage.
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The ApoE Gene Apolipoprotein E is a plasma lipoprotein implicated mainly in transporting cholesterol and lipids throughout tissues including the CNS. In the brain, ApoE is synthesized primarily by the astrocytes and the microglia and plays a vital role in the maintenance of neuronal membranes, neuronal tissue repair, remodeling, and synaptogenesis. Apolipoprotein E-deficient mice showed increased ischemic neuronal damage compared with wild-type mice. 45 It has been demonstrated that intraventricular infusion of ApoE reduces neuronal damage. 46 After CNS insults, ApoE is locally upregulated and released by the astrocytes into the extracellular space, and is subsequently absorbed by the neurons. 44 In humans, there are 3 major isoforms of ApoE (ε2, ε3, and ε4), which differ in amino acid sequence at positions 112 and 158. In the ApoE4 isoform, the amino acid substitution predisposes the protein to reduced stability, and this mediates an interaction between domains, which subsequently results in a more compact structure. 76 This conformation variation is thought to account for the adverse pathological functions of the ApoE4 isoform.
The ApoE4 isoform was found to bind Aβ peptides with a higher avidity, 124 and to promote more rapid aggregation into amyloid fibrils. 123 In a previous experimental head-injury study in mice, fatality was found to be increased in the ε4 isoform group among animals with different isoforms of ApoE. 114 The ApoE isoforms also show different interactions with tau protein, a microtubule-associated protein. Apolipoprotein E3 forms a stable complex with tau, preventing it from phosphorylation, aggregation, and formation of neurofibrillary tangles. In addition, it has been demonstrated that ApoE3 increases neurite outgrowth in cultures of dorsal root ganglion neurons compared with ApoE4. 97 These effects of ApoE3 on sprouting and synaptic remodeling are probably mediated by its effect on microtubule stability.
The ApoE4 isoform has also been associated with neurotoxicity and neurodegeneration, inflammation, mitochondrial dysfunction, impairment of the antioxidative defense system, increased intracellular calcium, disruption of cholinergic transmission, dysregulation of the neuronal signaling pathways, and apoptosis. 55, 76 Evidence from epidemiological and pathological studies has linked TBI to Alzheimer disease. 93 Deposition of Aβ was detected in approximately 30% of individuals dying shortly after severe TBI, 111 and this may imply a genetic predisposition to Aβ accumulation. In head-injured individuals, Aβ deposition was shown to be determined, though in part, by the presence of the ApoE4 allele. 100 Furthermore, immunostaining of amyloid deposits, which appear early after head injury, was positive for ApoE, whereas the number of immunoreactive plaques was associated with the ApoE4 allele in a dose-dependent manner. 43 Several association studies have investigated the role of the ApoE gene polymorphism in patients sustaining TBI. 55 The design and results of each study are summarized in Table 1 . Despite all the possible limitations, these studies provide valuable information concerning the implication of the ApoE genotype in the pathophysiology of TBI.
Most genetic studies in TBI have investigated possible association between ApoE polymorphism and functional outcome after TBI measured by the GOS. 2, 12, 15, 17, 25, 40, 69, 87, 98, 130, 131, 135 In a recent meta-analysis of 14 cohort studies (of 23 relevant studies identified from the literature) and 2427 participants, it was found that the ApoE4 allele increases the risk of poor clinical outcome, which was evaluated 6 months after the injury. 139 The ApoE polymorphism was also tested in patients who had suffered TBI in relation to several other neuropathological, laboratory, or imaging intermediate phenotypes, such as Aβ deposition, 100 hippocampal volume and brain atrophy, 48 cerebral blood flow, 59 presence of brain lesions, 41 In addition to the aforementioned coding sequence polymorphisms, the ApoE gene is also polymorphic in the regulatory region. Promoter −219G/T and −491A/T polymorphisms were found to substantially alter the transcriptional activity of the ApoE gene. 8 It has been reported that these polymorphisms confer susceptibility to Alzheimer disease, 10 possibly by facilitating the Aβ deposition. 64 However, in patients who have suffered TBI, the effects of promoter polymorphisms have remained inconclusive.
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Neprilysin
The accumulation of β-amyloid peptide in some patients shortly after TBI may be the result of an imbalance between production and clearance of Aβ. Of note, a major therapeutic strategy for Alzheimer disease is the activation of proteases involved in the Aβ degradation process. One such protease is neprilysin, which was found to play the most important role in the degradation of Aβ. 49 Neprilysin levels were decreased in cerebral cortex and CSF in cases of early Alzheimer disease. 79, 113 In addition, knockout models for neprilysin were shown to have an increased burden of brain Aβ, while overexpression of neprilysin was associated with reduction in Aβ levels and retardation of plaque formation. 49, 90 However, it seems that neprilysin may not have an effect on the removal of already existing amyloid plaques but only on the prevention of forming new amyloid plaques. 89 A GT repeat polymorphism in the neprilysin gene was shown to be associated with cerebral amyloid angiopathy and increased risk of Alzheimer disease. 115, 138 The polymorphism is located in the regulatory region of the nep rilysin gene, and it may induce conformational changes in the DNA, influence gene expression, and the degree of the Aβ degradation. In a recent study, this polymorphism was tested in 81 fatal cases of TBI with available autopsy data and a 3.45-day mean survival after injury. It was found that TBI cases with longer GT repeats had increased risk of Aβ plaques, 54 suggesting that neprilysin polymorphism may make patients who have suffered TBI more vulnerable to plaque formation. 
The p53 Gene
Experimental and clinical studies have provided evidence of widespread local and remote apoptosis that can be detected from hours to days after TBI. These studies have indicated that apoptosis following TBI occurs in neurons and glia and may contribute to neurological dysfunction. 108, 120 Apoptotic cell death after TBI has been associated with decreased expression of survival-promoting proteins, such as Bcl-2 and extracellular signal-regulated kinase and increased expression of death-inducing proteins, such as Bax, c-Jun N-terminal kinase, p53, calpain, and caspases. 99, 108 Interestingly, minocycline, a tetracycline derivative currently being tested in spinal cord injury, has been reported to exert neuroprotective and antiapoptotic effects in TBI via inhibition of cytochrome c release, inhibition of caspase-1 and -3, and expression and suppression of microglial activation. 116 The p53 tumor suppressor factor is a key regulator of DNA repair, cell cycle progression, apoptosis, and neuronal damage; 21 p53 is induced shortly after TBI, while its inhibition is assumed to offer neuroprotection. 96, 137 A functional polymorphism of the p53 gene in codon 72, which alters the properties of the produced protein, 27 was studied in a group of 90 severely head-injured patients who were admitted to an intensive care unit. 78 Patients with the Arg/Arg genotype were associated with unfavorable outcome at the time of discharge. However, 6 months later, no significant difference was found between the groups of patients with and without the Arg/Arg genotype, which may suggest a limited role of p53 in affecting the long-term clinical outcome of patients who have sustained TBI.
The ACE Gene
Angiotensin converting enzyme plays an important role in regulating both the production of angiotensin II and the degradation of bradykinin at the endothelial surface. Angiotensin II, which is the main active product of the renin-angiotensin system, has been linked to vascular remodeling, inflammation, and endothelial dysfunction.
28
The ACE insertion/deletion polymorphism has been extensively studied in various diseases. It has been associated, among others, with atherosclerosis 118 and Alzheimer disease. 66 The ACE insertion/deletion polymorphism appears to be of particular clinical significance as it alters the ACE plasma levels 110 and the local tissue production. 19, 23 However, the polymorphism only partially (47% in the study group) determines the variation in plasma ACE levels, 110 and it is uncertain if it represents a functional polymorphism. Actually, despite considerable efforts, the precise location of the ACE gene functional polymorphism among the several polymorphic sites that have been described remains unknown. 119 Ariza et al. 6 studied 73 patients who suffered moderate or severe TBI and reported worse neuropsychological performance in the D allele carriers of the ACE insertion/deletion polymorphism. The authors attributed this association to changes in the blood flow and cerebrovascular tone mediated by the local production of angiotensin II. Angiotensin II can also induce neuronal damage because it was found to have proinflammatory properties and to be implicated in the generation of reactive oxygen species.
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The IL Genes Brain injury induces a complex sequence of inflammatory processes, which are believed to contribute to the pathogenesis of TBI. 85 The level of these processes determines the patient's clinical presentation and outcome. 3, 91, 92 Interleukins are induced in response to brain injury and have multiple actions and targets, and often overlapping biological effects. Interleukin-1α and -1β are proinflammatory cytokines with pleiotropic activities, including growth and differentiation of T and B cells, and induction of other interleukins, adhesion molecules, histamine, and thromboxane. Interleukin-1 receptor antagonist (IL-1ra) is a naturally occurring competitive inhibitor of IL-1α and IL-1β and, as such, plays an important role in regulating the inflammatory process. 5, 26 In experimental TBI models, rapid induction of IL-1β was reported 42 after brain trauma (increased mRNA concentration occurred 15 minutes after the injury, while increased concentration of the involved protein occurred 6 hours after the injury). Similarly, IL-1ra was upregulated after head injury in the same experimental study (increased concentration of mRNA was observed 6 hours after the injury). Furthermore, administration of exogenous IL-1β markedly exacerbates brain injury, 102 whereas injection or overexpression of IL-1ra significantly inhibits neuronal damage. 133 Additionally, increased IL-1 expression is also detected in CSF in patients with head injury. 84 A randomized phase II study of IL-1ra in acute stroke patients has reported promising results. 30 The IL1 gene cluster contains genes encoding IL-1α, IL-1β, and IL-1ra and lies on 2q13 within the 430-kb region in humans. A variable number tandem repeat (VNTR) polymorphism in intron 2 of the IL1ra gene appears to be of particular clinical significance, as it has been associated with a variety of inflammatory diseases. 129 Carriers of the 2-repeat allele (IL1RN*2) have increased IL-1ra plasma levels, enhanced IL-1β production, and decreased local production of IL-1ra in various tissues. 117 Two polymorphisms of the IL-1β gene have been studied extensively in the +3953 and −511 positions. The minor alleles of both polymorphisms are considered to be high producers of IL-1β protein.
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Uzan et al. 134 first provided evidence of an association between IL-1β +3953 and −511 polymorphisms and unfavorable prognosis in patients who had sustained TBI. In another study, the IL1RN*2 allele carriers were associated with an increased risk of posttraumatic hemorrhagic events, which were used as an intermediate phenotype.
37 Surprisingly, the IL1RN*2 allele was associated with more severe initial clinical presentation (p = 0.045) and better clinical outcome (p = 0.02). These results may suggest that the increased inflammatory processes in IL1RN*2 allele carriers may be deleterious in the acute postinjury period, but may participate in neuronal survival and repair in the intermediate and chronic postinjury period, possibly reflecting the dual role of cytokines in neurodegeneration and neuroprotection. 3, 91, 92 Regarding the IL-1α gene, a polymorphism in the promoter region (−889) has been studied in various diseases. Although the IL-1α (−889) allele 2 was associated with elevated IL-1α and IL-1β protein levels, the functional role of this polymorphism has been questioned. 24 Two studies have investigated the role of this polymorphism in patients who have sustained a TBI, but these studies were not able to establish any positive association. 24, 128 In another study that included patients who had suffered severe TBI and provided autopsy data, Johnson et al. 53 examined a possible association between IL-1α and IL-1β polymorphisms and the extent of programmed cell death. Interestingly, the amount of TUNEL positivity did not differ between genotypes.
Another cytokine that is implicated in TBI pathophysiology is IL-6. Interleukin-6 has regulatory, antiinflammatory, and neurotrophic effects and is associated with neuronal protection and survival. 92 It has been demonstrated that IL-6-deficient mice have increased numbers of apoptotic neurons after brain injury. 103 However, administration of IL-6 can either enhance or inhibit neuronal injury, probably depending on the time course and extent of expression. 4 In patients who have suffered TBI, the concentrations of IL-6 in CSF were elevated, and this upregulation after injury was associated with better neurological outcome. 18 However, a polymorphism in the promoter of IL6 was not found to have any effect on the outcome of patients with TBI.
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Other Association Studies
Clinical studies in patients who have sustained TBI have investigated the role of genetic variants in genes that modulate neurotransmitters such as dopamine 81 or serotonin. 16 Traumatic brain injury induces excessive neurotransmitter release, and this may affect motor function, behavior, mood, and cognition. Dopamine and noradrenaline are key neurotransmitters that regulate cognitive function and affective behavioral processes. Dopamine and noradrenaline interact with specific receptors or are inactivated by COMT. Catechol-O-methyltransferase Val158Met polymorphism is associated with variation in COMT activity. The 158Met allele, which decreases the activity of the enzyme, is associated with higher dopamine concentrations in the prefrontal cortex 63 and possibly with better cognitive performance. In patients who have suffered TBI, the COMT genotype was associated with higher postinjury performance on tests of executive function. 72 In another study, a polymorphism in the ANKK1 gene, which regulates the adjacent dopamine D2 receptor gene, causing a reduction in the expression of D2 receptors, was found to be associated with slower postinjury performance on response latency. 82, 83 Depression is among the most common postinjury sequelae and may contribute to posttraumatic disability. Depression after TBI may be the result of a disturbance in serotonergic neurotransmission. 22 However, a polymorphism in serotonin transporter protein (SLC6A4 solute carrier family 6 member 4) was not associated with increased frequency of depression after TBI. 16 
Conclusions
Over the past years, there has been extensive research in elucidating the pathophysiology of TBI and the determinants of patient outcome, whereas it remains to be seen if this knowledge will lead to the induction of new treatment strategies and improved clinical outcome. Several association studies have revealed a number of genetic variants that confer susceptibility to poor outcome after TBI. Apart from providing insights into the pathophysiology of TBI, genetic studies may have some useful implications including the development of genetic markers for determination of specific molecular profiles in individuals and assessment of phenotype risk. Identification of ApoE alleles may determine which patients with TBI will respond, for example, to ApoE administration or to targeted therapies, such as bapineuzumab, which is currently being tested in patients with Alzheimer disease who have a specific ApoE genotype. It is also possible that detection of genetic markers, such as IL high-risk alleles, may help in identifying those patients who have sustained TBI with a specific proinflammatory or antiinflammatory phenotype, who may benefit from an early antiinflammatory treatment. This may, in part, explain the lack of clear clinical efficacy in improving outcome of previous antiinflammatory-based treatment trials in patients suffering TBI. 1 Furthermore, our better understanding of complex genetic pathways may lead to specific genetic manipulation, for example, by targeting genetic modulators such as promoter regions, 47 in the near future. There is also the possibility of neutralizing pathological mRNA, protein products and secondary messengers.
11 Genetic determination of patients' functional alterations in metabolic enzymes may also have a clear beneficial effect on developing specific treatment strategies. It is possible that this pharmacogenomics approach may have a clear impact in determining the optimal therapeutic doses, minimizing the possibility of any side effects, and improving treatment adherence and efficacy. 13 In the future, all of these approaches may offer the prospect of personalized risk assessment and novel, genomic-based, targeted therapies.
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